NeuroMetrix (NURO) Earning Somewhat Favorable Press Coverage, Study Finds

News stories about NeuroMetrix (NASDAQ:NURO) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NeuroMetrix earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.1165587389946 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective (down previously from $10.00) on shares of NeuroMetrix in a research note on Friday, October 20th.

NeuroMetrix (NURO) traded up $0.17 on Monday, hitting $1.68. The stock had a trading volume of 262,100 shares, compared to its average volume of 84,048. NeuroMetrix has a 12 month low of $1.45 and a 12 month high of $9.60.

TRADEMARK VIOLATION NOTICE: “NeuroMetrix (NURO) Earning Somewhat Favorable Press Coverage, Study Finds” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://ledgergazette.com/2017/12/11/neurometrix-nuro-earning-somewhat-favorable-press-coverage-study-finds.html.

NeuroMetrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Insider Buying and Selling by Quarter for NeuroMetrix (NASDAQ:NURO)

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply